Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.
To the Editor: Dr Trinh and colleagues1 concluded that ChIs have a "modest beneficial impact
on neuropsychiatric and functional outcomes for patients with AD." The differences,
in fact, were exceedingly small.
The most important point of view, though, is that of the caregivers.
It would be of interest to know if there were data about whether they thought
that these drugs provided benefit to their loved ones, or whether they themselves
had any improvement in their quality of life. If not, then I would interpret
these results as clinically insignificant.
Finucane TE. Cholinesterase Inhibitors for Alzheimer DiseaseCholinesterase Inhibitors for Alzheimer Disease. JAMA. 2003;289(18):2359. doi:10.1001/jama.289.18.2359-a